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UK investments in global infectious disease research 
1997–2010: a case study
Michael G Head, Joseph R Fitchett, Mary K Cooke, Fatima B Wurie, Andrew C Hayward, Rifat Atun
Summary
Background Infectious diseases account for 15 million deaths per year worldwide, and disproportionately aﬀ ect young 
people, elderly people, and the poorest sections of society. We aimed to describe the investments awarded to UK 
institutions for infectious disease research.
Methods We systematically searched databases and websites for information on research studies from funding 
institutions and created a comprehensive database of infectious disease research projects for the period 1997–2010. 
We categorised studies and funding by disease, cross-cutting theme, and by a research and development value chain 
describing the type of science. Regression analyses were reported with Spearman’s rank correlation coeﬃ  cient to 
establish the relation between research investment, mortality, and disease burden as measured by disability-adjusted 
life years (DALYs).
Findings We identiﬁ ed 6170 funded studies, with a total research investment of UK£2·6 billion. Studies with a clear 
global health component represented 35·6% of all funding (£927 million). By disease, HIV received £461 million 
(17·7%), malaria £346 million (13·3%), tuberculosis £149 million (5·7%), inﬂ uenza £80 million (3·1%), and 
hepatitis C £60 million (2·3%). We compared funding with disease burden (DALYs and mortality) to show low levels 
of investment relative to burden for gastrointestinal infections (£254 million, 9·7%), some neglected tropical diseases 
(£184 million, 7·1%), and antimicrobial resistance (£96 million, 3·7%). Virology was the highest funded category 
(£1 billion, 38·4%). Leading funding sources were the Wellcome Trust (£688 million, 26·4%) and the Medical 
Research Council (£673 million, 25·8%).
Interpretation Research funding has to be aligned with prevailing and projected global infectious disease burden. 
Funding agencies and industry need to openly document their research investments to redress any inequities in 
resource allocation.
Funding None.
Introduction
Infectious diseases cause a high burden of largely 
avoidable morbidity and mortality worldwide, and place 
substantial strain on the limited health budgets, health 
systems, and economies of aﬀ ected countries. WHO 
ﬁ gures1 for low-income countries suggest that infections 
of the lower respiratory tract are the leading cause of 
death, followed by ischaemic heart disease, with 
diarrhoeal disease the third highest and HIV/AIDS the 
fourth highest cause of death. Although infectious 
disease control is of the utmost importance for human 
health, global health security, economic stability, and 
international develop ment do not have a comprehensive 
surveillance system to document and monitor infectious 
disease research investments.
Many factors aﬀ ect the fairly low level of investment in 
research and development for infectious diseases and 
maternal, neonatal, and child health. These factors 
include market failure2–4 because of low ﬁ nancial 
opportunities for private investors, risks of research 
(especially in children and pregnant women), and 
fragmented infrastructure to do trials for infections and 
disorders aﬀ ecting populations in low-income countries. 
Funding for these diseases has been from donor 
governments, philanthropic organisations, and public–
private partnerships.
Infections do not recognise borders. Investment in 
research and development for infectious diseases pro-
duces global public beneﬁ ts that have a positive eﬀ ect both 
locally and worldwide, irrespective of the site of the work 
or the location of the institution receiving an award, 
bringing substantial health, social, and economic beneﬁ t.2,5
In view of the scarcity of resources available, funds for 
research and development should take into account the 
local and global burdens of disease. Since 2007, the 
G-FINDER project, originally commissioned by the Bill 
& Melinda Gates Foundation, annually surveys global 
neglected disease research and development expend-
iture.6,7 Studies to assess the research spend according to 
the burden of disease, with data sourced from Australia, 
Canada, Spain, and the USA,8–11 have had diﬃ  culties 
because of poor data availability. The UK is the second 
largest investor in global health, but there has been no 
detailed analysis of its research investment. A study by 
the UK Clinical Research Collaboration con sidered the 
broad direction of research funding across all medical 
specialties, but was restricted to one ﬁ nancial year.12 
Investments from the UK pharmaceutical industry (a key 
Lancet Infect Dis 2013; 13: 55–64 
Published Online
November 8, 2012
http://dx.doi.org/10.1016/
S1473-3099(12)70261-X
See Comment page 6
University College London, 
Research Department of 
Infection and Population 
Health, UCL Royal Free Campus, 
London, UK (M G Head PGDip, 
M K Cooke MSc, F B Wurie BSc, 
A C Hayward MD); London 
School of Hygiene and Tropical 
Medicine, Keppel Street, 
London, UK (J R Fitchett MSc); 
and Imperial College Business 
School and the Faculty of 
Medicine, Imperial College 
London, South Kensington 
Campus, London, UK 
(R Atun FRCP)
Correspondence to:
Mr Michael G Head, University 
College London, Research 
Department of Infection and 
Population Health, UCL Royal 
Free Campus, Rowland Hill 
Street, London, NW3 2PF, UK
m.head@ucl.ac.uk
Articles
56 www.thelancet.com/infection   Vol 13   January 2013
investor in infectious disease research) are poorly 
documented, partly because of commercial sensitivity.12
There are large gaps in our quantiﬁ cation of the 
worldwide spend on infectious disease research and the 
translation of funds along the research and development 
value chain into health policy and practice. We present 
an in-depth analysis examining the investments awarded 
to UK institutions for all infectious disease research, over 
the 14 year period from 1997 to 2010. The aims of our 
study were to quantify awards to UK institutions for local 
and global infectious disease research; to establish the 
clinical diseases, specialties, and study types targeted by 
the major funders; and to identify potential areas of 
historical and current underinvestment.
Methods
Data sources
We obtained data from several sources for studies 
where funding was awarded between 1997 and 2010. 
Variables collected included study title, abstract, funding 
awarded to the study, lead institution, principal inves-
tigator, and year of award. 70 principal investigators were 
contacted individually for further information where 
needed. We include in the appendix the full list of key-
words used to search databases and websites belonging 
to funding agencies. We also searched ClinicalTrials.gov, 
the National Research Register, and the Association of 
Medical Research Charities database.
Inclusion criteria
We used the study title and abstract (where present) as 
a ﬁ lter, and included all infection-related studies with 
funding awarded in the period 1997–2010, studies 
where the lead institution was based in the UK, and 
infrastructure grants with a clear purpose for infectious 
disease research. This period was selected on the basis of 
accurate data availability, which enabled us to suitably 
compare our results with the WHO burden estimates of 
2004 and 2008. We excluded studies not immediately 
relevant to infection, veterinary infectious disease research 
studies (unless there was a clear zoonotic component), 
studies where viral vectors were used to investigate non-
communicable diseases, grants for symposia or meetings, 
and studies where there were UK contributions (eg, as a 
collaborator) but the funding was awarded to a non-UK 
institution. Where there was uncertainty, the study author 
was contacted or further details were sourced from the 
internet. Of the studies included in the ﬁ nal database, all 
had a title and 58% had an abstract. We excluded open-
access data from the pharmaceutical industry since it was 
clearly under-representative.
Data management
Grants awarded in a currency other than pounds sterling 
were converted to UK pounds using the mean exchange 
rate in the year of the award. All grant funding amounts 
were adjusted for inﬂ ation and reported in 2010 UK 
pounds. Grants were not modiﬁ ed according to levels of 
overheads applied to the award. For multicentre studies, 
any distribution of funding from the lead centre where 
the award was made to other study sites was not 
documented. Unfunded studies were excluded from our 
analysis.
Each study in the database was reviewed by MGH 
and assigned to as many primary disease categories 
as appropriate (appendix). Within each category, topic-
speciﬁ c subsections were documented.
Studies were also allocated to one of four research 
and development categories: pre-clinical; phase 1, 2, or 3; 
product development; and operational research (appen-
dix). All studies were categorised and subsequently 
double-checked by JRF. Provisional datasets were 
circulated to all authors for review and comment. MKC 
and FBW further veriﬁ ed a random sample of 10% of the 
data (663 studies) in a third round of checks. The ﬁ xed 
marginal κ score was 0·950 suggesting high agreement 
between the authors when categorising studies. All 
diﬀ erences on inclusion or categorisation were discussed 
between MGH and the author who ﬂ agged the study, and 
where there was still disagreement, the data were 
For yearly average exchange 
rate see http://www.oanda.com/ 
325 922 studies screened
                  170 452 National Research Register
                     25 113 European Commission
                        7513 Bill & Melinda Gates Foundation
                    14 660 Wellcome Trust
                       1074 Health Technology Assessment
                       6346 ESRC
                            30 Healthcare Infection Society
                       1583 British Heart Foundation
                         266 Action Medical Research
                            27 National Institute for Health Research
                            24 British HIV Association
                          150 British Lung Foundation
                            65 British Society for Antimicrobial Chemotherapy
                   98 619 National Institute for Health
314 867 studies excluded
                 Not infection-related
                 Veterinary studies
                 Non-UK host recipient
9750 studies eligible for detailed review
3580 studies excluded from analysis
            Unfunded studies
            Industry funded
6170 studies eligible for analysis
4240 studies provided to authors
            2016 Medical Research Council
               321 BBRSC
                 55 Meningitis UK
               272 Meningitis Research Foundation
               747 Association of Medical Research Charities
                 52 Department for International Development
              547 Cancer Research UK
                60 Chief Scientist’s Oﬃce, Scotland
                 41 Health Protection Agency
                 34 Northern Ireland R&D oﬃce
                 95 directly from researchers
Figure 1: Sources and numbers of studies screened
ESRC=Economic and Social Research Council. BBSRC=Biotechnology and Biological Sciences Research Council.
See Online for appendix
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Investment 
(total), £ (%)
Studies, 
n (%)
Investment 
(1997–2004)
2004 
mortality, 
n (%)
2004 
DALYs, 
n (%)
Investment (2005–10) 2008 mortality 
(projected), 
n (%)
2008 DALYs 
(projected), 
n (%)
£ (%) n (%) £ (%) n (%)
Disease system
Gastrointestinal 
infections
254 006 242 
(9·7%)
799 
(12·9%)
130 548 965 
(9·5%)
498 
(12·6%)
2 169 764 
(22·2%)
76 789 182 
(25·1%)
123 457 277 
(10·0%)
301 
(13·5%)
1 691 818 
(19·8%)
59 244 563 
(22·2%)
Haematological 
infections
413 489 870 
(15·9%)
742 
(12·0%)
190 188 198 
(13·9%)
504 
(12·8%)
889 186 
(9·1%)
33 976 026 
(11·1%)
223 301 672 
(18·0%)
238 
(10·7%)
836 624 
(9·8%)
32 342 189 
(12·1%)
Hepatic 
infections
73 965 716 
(2·8%)
322 
(5·2%)
48 859 066 
(3·6%)
251 
(6·4%)
199 792 
(2·0%)
4 769 299 
(1·6%)
25 106 651 
(2·0%)
71 
(3·2%)
172 068 
(2·0%)
3 907 550 
(1·5%)
Neglected 
tropical diseases
184 446 162 
(7·1%)
392 
(6·4%)
113 018 076 
(8·3%)
267 
(6·8%)
182 153 
(1·9%)
18 323 958 
(6·0%)
71 428 087 
(5·8%)
125 
(5·6%)
149 693 
(1·8%)
14 969 564 
(5·6%)
Neurological 
infections
101 363 708 
(3·9%)
339 
(5·5%)
62 685 767 
(4·6%)
241 
(6·1%)
392 292 
(4·0%)
13 099 105 
(4·3%)
38 677 941 
(3·1%)
98 
(4·4%)
314 617 
(3·7%)
10 231 400 
(3·8%)
Ocular 
infections
7 407 218 
(0·3%)
36 
(0·6%)
3 574 775 
(0·3%)
27 
(0·7%)
173 
(0·0%)
1 722 990 
(0·6%)
3 832 443 
(0·3%)
9 
(0·4%)
153 
(0·0%)
1 487 567 
(0·6%)
Respiratory 
infections
410 705 744 
(15·8%)
1190 
(19·3%)
197 356 636 
(14·4%)
737 
(18·7%)
4 258 563 
(43·5%)
97 786 126 
(32·0%)
213 349 109 
(17·2%)
453 
(20·3%)
3 815 503 
(44·7%)
81 583 751 
(30·6%)
Sexually-
transmitted 
infections
138 581 653 
(5·3%)
380 
(6·2%)
96 118 502 
(7·0%)
259 
(6·6%)
396 717 
(4·1%)
14 144 219 
(4·6%)
42 463 150 
(3·4%)
121 
(5·4%)
393 239 
(4·6%)
13 186 581 
(4·9%)
HIV 460 547 457 
(17·7%)
760 
(12·3%)
243 453 711 
(17·8%)
479 
(12·2%)
2 039 727 
(20·8%)
58 512 843 
(19·1%)
217 093 746 
(17·5%)
281 
(12·6%)
2 242 597 
(26·3%)
64 661 516 
(24·2%)
Overall 2 606 482 941 6170 1 367 696 262 3941 9 786 907 305 863 590 1 238 786 678 2229 8 533 171 266 845 840
Speciﬁ c infection
African 
trypanosomiasis
48 082 259 
(2·6%)
116 
(2·9%)
25 831 831 
(2·7%)
73 
(2·7%)
52 347 
(0·8%)
1 672 728 
(0·8%)
22 250 428 
(2·6%)
43 
(3·2%)
44 490 
(0·7%)
1 408 517 
(0·7%)
Aspergillus 4 853 858 
(0·3%)
26 
(0·7%)
3 950 124 
(0·4%)
27 
(1·0%)
·· ·· 933 213 
(0·1%)
4 
(0·3%)
·· ··
Campylobacter 24 116 021 
(1·3%)
87 
(2·2%)
12 072 058 
(1·3%)
47 
(1·8%)
·· ·· 12 198 511 
(1·4%)
43 
(3·2%)
·· ··
Candida 1 219 072 
(0·1%)
8 
(0·2%)
237 210 
(0·0%)
8 
(0·3%)
·· ·· 1 028 298 
(0·1%)
2 
(0·1%)
·· ··
Chagas disease 3 448 856 
(0·2%)
15 
(0·4%)
2 522 761 
(0·3%)
12 
(0·5%)
11 367 
(0·2%)
429 873 
(0·2%)
926 096 
(0·1%)
3 
(0·2%)
10 066 
(0·2%)
341 578 
(0·2%)
Chlamydia 21 702 378 
(1·2%)
112 
(2·8%)
17 462 388 
(1·8%)
73 
(2·7%)
8889 
(0·1%)
3 748 198 
(1·8%)
4 239 990 
(0·5%)
39 
(2·9%)
7421 
(0·1%)
3 420 418 
(1·8%)
Clostridium 29 751 310 
(1·6%)
72 
(1·8%)
5 164 027 
(0·5%)
23 
(0·9%)
·· ·· 25 199 334 
(2·9%)
51 
(3·8%)
·· ··
Cytomegalovirus 28 369 415 
(1·6%)
68 
(1·7%)
18 988 235 
(2·0%)
60 
(2·3%)
·· ·· 9 581 430 
(1·1%)
14 
(1·0%)
·· ··
Dengue 43 742 101 
(2·4%)
28 
(0·7%)
4 430 589 
(0·5%)
15 
(0·6%)
18 104 
(0·3%)
669 648 
(0·3%)
39 311 513 
(4·5%)
13 
(1·0%)
12 899 
(0·2%)
470 201 
(0·2%)
Diphtheria 139 863 
(0·0%)
2 
(0·1%)
139 863 
(0·0%)
2 
(0·1%)
5091 
(0·1%)
173 575 
(0·1%)
0 
(0·0%)
0 
(0·0%)
3933 
(0·1%)
132 303 
(0·1%)
Escherichia coli 25 589 407 
(1·4%)
106 
(2·7%)
15 852 833 
(1·7%)
74 
(2·8%)
·· ·· 9 760 027 
(1·1%)
33 
(2·4%)
·· ··
Epstein-Barr 
virus
45 310 414 
(2·5%)
147 
(3·7%)
32 961 882 
(3·5%)
114 
(4·3%)
·· ·· 12 348 532 
(1·4%)
33 
(2·4%)
·· ··
Gonorrhoea 948 399 
(0·1%)
18 
(0·5%)
768 377 
(0·1%)
14 
(0·5%)
559 
(0·0%)
3 549 976 
(1·7%)
180 021 
(0·0%)
4 
(0·3%)
474 
(0·0%)
3 316 666 
(1·7%)
Helicobacter 15 109 554 
(0·8%)
101 
(2·6%)
12 924 723 
(1·4%)
96 
(3·6%)
·· ·· 2 262 304 
(0·3%)
13 
(1·0%)
·· ··
Helminths 47 026 454 
(2·6%)
114 
(2·9%)
25 762 808 
(2·7%)
77 
(2·9%)
47 858 
(0·8%)
11 660 451 
(5·5%)
21 263 645 
(2·4%)
37 
(2·7%)
41 357 
(0·7%)
9 609 061 
(4·9%)
Hepatitis B 11 768 095 
(0·6%)
68 
(1·7%)
9 829 208 
(1·0%)
57 
(2·1%)
104 606 
(1·7%)
2 067 533 
(1·0%)
1 938 888 
(0·2%)
11 
(0·8%)
88 653 
(1·5%)
1 668 641 
(0·9%)
Hepatitis C 59 727 829 
(3·3%)
235 
(5·9%)
38 124 617 
(4·0%)
182 
(6·8%)
54 099 
(0·9%)
994 622 
(0·5%)
21 603 212 
(2·5%)
53 
(3·9%)
46 906 
(0·8%)
782 184 
(0·4%)
(Continues on next page)
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Investment 
(total), £ (%)
Studies, 
n (%)
Investment 
(1997–2004)
2004 
mortality, 
n (%)
2004 
DALYs, 
n (%)
Investment (2005–10) 2008 mortality 
(projected), 
n (%)
2008 DALYs 
(projected), 
n (%)
£ (%) n (%) £ (%) n (%)
(Continued from previous page)
HIV 460 547 457 
(25·3%)
760 
(19·2%)
243 453 711 
(25·6%)
479 
(18·0%)
2 039 727 
(32·2%)
58 512 843 
(27·7%)
217 093 746 
(24·9%)
281 
(20·7%)
2 242 597 
(37·7%)
64 661 516 
(33·3%)
Human 
papillomavirus
57 795 110 
(3·2%)
150 
(3·8%)
41 452 682 
(4·4%)
108 
(4·1%)
268 245 
(4·2%)
3 719 348 
(1·8%)
16 342 428 
(1·9%)
42 
(3·1%)
286 451 
(4·8%)
3 906 185 
(2·0%)
Herpes simplex 
virus
22 063 300 
(1·2%)
48 
(1·2%)
18 201 738 
(1·9%)
57 
(2·1%)
·· ·· 4 694 523 
(0·5%)
13 
(1·0%)
·· ··
Inﬂ uenza 79 763 001 
(4·4%)
140 
(3·5%)
29 388 916 
(3·1%)
42 
(1·6%)
·· ·· 50 629 034 
(5·8%)
101 
(7·4%)
·· ··
Leishmaniasis 36 027 609 
(2·0%)
75 
(1·9%)
16 156 050 
(1·7%)
47 
(1·8%)
46 862 
(0·7%)
1 974 465 
(0·9%)
19 871 559 
(2·3%)
28 
(2·1%)
35 881 
(0·6%)
1 486 268 
(0·8%)
Leprosy 623 080 
(0·0%)
2 
(0·1%)
623 080 
(0·1%)
2 
(0·1%)
5442 
(0·1%)
193 803 
(0·1%)
0 
(0·0%)
0 
(0·0%)
4847 
(0·1%)
166 371 
(0·1%)
Listeria 4 751 097 
(0·3%)
10 
(0·3%)
3 947 669 
(0·4%)
8 
(0·3%)
·· ·· 803 428 
(0·1%)
2 
(0·1%)
·· ··
Lymphatic 
ﬁ lariasis
51 112 541 
(2·8%)
16 
(0·4%)
3 679 045 
(0·4%)
10 
(0·4%)
290 
(0·0%)
5 940 641 
(2·8%)
47 433 496 
(5·4%)
6 
(0·4%)
252 
(0·0%)
4 878 733 
(2·5%)
Malaria 346 180 494 
(19·0%)
501 
(12·7%)
165 764 640 
(17·4%)
340 
(12·8%)
889 186 
(14·0%)
33 976 026 
(16·1%)
180 415 854 
(20·7%)
161 
(11·9%)
836 624 
(14·1%)
32 342 189 
(16·6%)
Measles 2 597 677 
(0·1%)
9 
(0·2%)
1 630 534 
(0·2%)
7 
(0·3%)
423 710 
(6·7%)
14 852 775 
(7·0%)
967 143 
(0·1%)
2 
(0·1%)
327 744 
(5·5%)
11 255 332 
(5·8%)
Meningitis 54 078 664 
(3·0%)
223 
(5·6%)
35 650 075 
(3·7%)
152 
(5·7%)
339 945 
(5·4%)
11 426 377 
(5·4%)
18 428 589 
(2·1%)
71 
(5·2%)
270 127 
(4·5%)
8 822 883 
(4·5%)
Norovirus 5 102 250 
(0·3%)
12 
(0·3%)
1 250 218 
(0·1%)
6 
(0·2%)
·· ·· 3 852 031 
(0·4%)
6 
(0·4%)
·· ··
Onchocerciasis 1 338 978 
(0·1%)
4 
(0·1%)
1 338 978 
(0·1%)
4 
(0·2%)
65 
(0·0%)
388 576 
(0·2%)
0 
(0·0%)
0 
(0·0%)
60 
(0·0%)
348 364 
(0·2%)
Pertussis 2 432 158 
(0·1%)
9 
(0·2%)
1 658 797 
(0·2%)
7 
(0·3%)
254 497 
(4·0%)
9 881 667 
(4·7%)
773 361 
(0·1%)
2 
(0·1%)
194 096 
(3·3%)
7 589 588 
(3·9%)
Polio 1 189 984 
(0·1%)
4 
(0·1%)
247 880 
(0·0%)
2 
(0·1%)
1195 
(0·0%)
34 399 
(0·0%)
942 103 
(0·1%)
2 
(0·1%)
1095 
(0·0%)
26 455 
(0·0%)
Pseudomonas 6 473 237 
(0·4%)
43 
(1·1%)
3 417 409 
(0·4%)
36 
(1·4%)
·· ·· 3 170 837 
(0·4%)
12 
(0·9%)
·· ··
Rotavirus 5 883 445 
(0·3%)
18 
(0·5%)
3 026 257 
(0·3%)
15 
(0·6%)
·· ·· 3 063 635 
(0·4%)
5 
(0·4%)
·· ··
Respiratory 
syncytial virus
16 899 738 
(0·9%)
45 
(1·1%)
11 187 246 
(1·2%)
37 
(1·4%)
·· ·· 6 158 406 
(0·7%)
13 
(1·0%)
·· ··
Salmonella 55 716 287 
(3·1%)
145 
(3·7%)
31 145 306 
(3·3%)
81 
(3·0%)
·· ·· 24 656 054 
(2·8%)
65 
(4·8%)
·· ··
Schistosomiasis 38 677 801 
(2·1%)
46 
(1·2%)
35 08658 117 
(3·7%)
38 
(1·4%)
41 087 
(0·6%)
1 707 144 
(0·8%)
3 591 684 
(0·4%)
8 
(0·6%)
36 509 
(0·6%)
1 456 725 
(0·7%)
Shigella 3 292 442 
(0·2%)
9 
(0·2%)
1 886 751 
(0·2%)
4 
(0·2%)
·· ·· 1 405 691 
(0·2%)
5 
(0·4%)
·· ··
Syphilis 1 061 560 
(0·1%)
5 
(0·1%)
775 444 
(0·1%)
3 
(0·1%)
99 167 
(1·6%)
2 846 113 
(1·3%)
286 117 
(0·0%)
2 
(0·1%)
81 164 
(1·4%)
2 305 151 
(1·2%)
Tetanus 1 228 583 
(0·1%)
6 
(0·2%)
1 228 583 
(0·1%)
6 
(0·2%)
162 867 
(2·6%)
5 283 485 
(2·5%)
0 
(0·0%)
0 
(0·0%)
128 258 
(2·2%)
4 190 231 
(2·2%)
Trachoma 1 928 640 
(0·1%)
3 
(0·1%)
608 792 
(0·1%)
1 
(0·0%)
108 
(0·0%)
1 334 414 
(0·6%)
1 319 848 
(0·2%)
2 
(0·1%)
93 
(0·0%)
1 139 203 
(0·6%)
Tuberculosis 148 801 691 
(8·2%)
327 
(8·3%)
70 024 830 
(7·4%)
202 
(7·6%)
1 463 792 
(23·1%)
34 216 721 
(16·2%)
78 776 861 
(9·0%)
125 
(9·2%)
1 249 975 
(21·0%)
28 696 686 
(14·8%)
Varicella zoster 
virus
4 186 583 
(0·2%)
20 
(0·5%)
2 131 877 
(0·2%)
18 
(0·7%)
·· ·· 2 264 526 
(0·3%)
6 
(0·4%)
·· ··
Total infections 1 820 658 688 3953 951 986 157 2666 6 339 105 211 255 401 871 966 395 1356 5 951 972 194 421 449
Overall 2 606 482 941 6170 1 367 696 262 3941 9 786 907 305 863 590 1 238 786 678 2229 8 533 171 266 845 840
All investment reported in 2010 UK pounds. DALYS=disability-adjusted life-years.
Table 1: Investment in cross-cutting theme and disease with associated measures of burden
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referred to a third author (MKC, FBW, or JRF) for their 
consideration and ﬁ nal decision.
Funding organisations were allocated to one of 
26 categories (appendix). Categories were deﬁ ned by the 
authors, initially based on a pilot of this work in 2006 and 
further reﬁ ned based on the total research investment of 
the funder and the providence of the investor’s funds. 
The category of antimicrobial resistance includes anti-
bacterial, antiviral, and antifungal resistance. Reference 
to diagnostics includes screening programmes. Refer-
ence to sexually transmitted infections excludes HIV. 
Neglected tropical diseases were categorised based on the 
infections focused on by WHO. Reference to cross-
cutting themes includes areas of research that apply to 
several infectious diseases such as antimicrobial 
resistance, drug development, and vaccination.
Data were sourced over 3 years (September, 2007, to 
December, 2010). Data categorisation was done between 
December, 2010, and April, 2012. Data were analysed 
between October, 2011, and May, 2012.
Statistical analysis
Microsoft Excel versions 2000 and 2007 were used for 
the categorisation of studies. Where needed, data were 
exported into Microsoft Access (versions 2000 and 2007) 
and speciﬁ c keyword queries used to select precise 
sections of the data for analysis. Statistical analysis and 
generation of ﬁ gures and graphs were done with Stata 
(version 11). Regression analyses were reported with 
Spearman’s rank correlation coeﬃ  cient (r) to establish 
the relation between research investment, mortality, and 
disease burden as measured by disability-adjusted life 
years (DALYs).13
Role of the funding source
There was no funding source for this study. The cor-
responding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
We identiﬁ ed 320 470 studies that were suitable for 
screening. Of these, 6170 funded studies met our in-
clusion criteria (ﬁ gure 1). The funding for these studies 
represented a total research investment of UK£2·6 billion 
(ﬁ gure 1). Worldwide, gastrointestinal disease represents 
a similar burden of mortality and DALYs as HIV but 
receives roughly half the research funding.1 Investment 
is similar when classiﬁ ed by research themes, health 
burden, and research. Table 1 shows a detailed break-
down of the investment by disease and cross-cutting 
themes, and the burden data. There are prominent 
disparities between investment and burden of speciﬁ c 
diseases. The type of science funded by each institution 
Investment, 
£ (%)
Studies, 
n (%) 
Pre-clinical Phase 1–3 Product 
development
Operational research
£ (%) n (%) £ (%) n (%) £ (%) n (%) £ (%) n (%)
Public funding 1 393 972 967 
(53·5%)
2281 
(37·0%)
·· ·· ·· ·· ·· ·· ·· ··
Biotechnology and 
Biological Sciences 
Research Council
186 268 429 
(7·1%)
578 
(9·4%)
186 243 256 
(100·0%)
576 
(99·7%)
0 
(0·0%)
0 
(0·0%)
0 
(0·0%)
0 
(0·0%)
25 173 
(0·0%)
2 
(0·3%)
UK Government, non 
Department of Health
144 831 562 
(5·6%)
237 
(3·8%)
12 858 143 
(8·9%)
74 
(31·2%)
59 803 751 
(41·3%)
6 
(2·5%)
5 979 916 
(4·1%)
34 
(14·3%)
66 189 752 
(45·7%)
123 
(51·9%)
Department of Health 134 961 745 
(5·2%)
285 
(4·6%)
14 317 188 
(10·6%)
28 
(9·8%)
6 840 563 
(5·1%)
7 
(2·5%)
20 373 031 
(15·1%)
40 
(14·0%)
93 430 963 
(69·2%)
210 
(73·7%)
Medical Research Council 672 895 698 
(25·8%)
962 
(15·6%)
527 370 055 
(78·4%)
738 
(76·7%)
42 323 395 
(6·3%)
43 
(4·5%)
27 578 378 
(4·1%)
35 
(3·6%)
75 623 870 
(11·2%)
146 
(15·2%)
European Commission 255 015 533 
(9·8%)
219 
(3·5%)
187 782 118 
(73·6%)
164 
(74·9%)
0 
(0·0%)
0 
(0·0%)
12 680 401 
(5·0%)
14 
(6·4%)
54 553 014 
(21·4%)
41 
(18·7%)
Philanthropy 1 108 966 983 
(42·5%)
2879 
(46·7%)
·· ·· ·· ·· ·· ·· ·· ··
Bill & Melinda Gates 
Foundation
220 923 242 
(8·5%)
39 
(0·6%)
40 318 109 
(18·2%)
8 
(20·5%)
4 747 473 
(2·1%)
5 
(12·8%)
5 407 891 
(2·4%)
4 
(10·3%)
170 449 769 
(77·2%)
22 
(56·4%)
Charity 199 703 382 
(7·7%)
855 
(13·9%)
136 625 522 
(68·4%)
529 
(61·9%)
4 993 262 
(2·5%)
40 
(4·7%)
3 620 490 
(1·8%)
35 
(4·1%)
54 464 109 
(27·3%)
251 
(29·4%)
Wellcome Trust 688 340 359 
(26·4%)
1985 
(32·2%)
486 184 312 
(70·6%)
1524 
(76·8%)
17 647 229 
(2·6%)
17 
(0·9%)
41 427 765 
(6·0%)
70 
(3·5%)
143 081 054 
(20·8%)
374 
(18·8%)
Other 103 542 992 
(4·0%)
1010 
(16·4%)
37 344 165 
(36·1%)
401 
(39·7%)
10 471 721 
(10·1%)
27 
(2·7%)
15 810 957 
(15·3%)
103 
(10·2%)
39 916 149 
(38·6%)
479 
(47·4%)
Overall 2 606 482 941 6170 ·· ·· ·· ·· ·· ·· ·· ··
All investment reported in 2010 UK pounds.
Table 2: Investment by funding source and research and development phase
For the list of neglected tropical 
diseases focused on by WHO 
see http://www.who.int/
neglected_diseases/diseases/en/
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varies according to their priorities. Wellcome Trust funds 
a greater number of preclinical studies, whereas the UK 
Government research portfolios are more focused on 
operational and implementation research (table 2).
More than a third of the total funding (£927·3 million) 
had an explicit global health component. This represents 
a minimum estimate because the distinction between 
locally focused and global research was not always clear. 
Mean funding for all infectious diseases was £186·2 mil-
lion per year (SD £75·8 million). Mean funding awarded 
per study was £422 445 (SD £1 316 020) with median 
funding per study substantially lower at £158 059 (IQR 
£49 657–£352 754).
Regression analysis between disease system and 
infection against DALYs shows a clear misalignment 
between investment and worldwide burden (ﬁ gure 2), 
with a moderate association of speciﬁ c infection research 
funding to DALYs in 2004 (r 0·5270) and a worsening 
association in 2008 (r 0·3203). Conversely, there is a 
positive association between infection by disease system 
and DALYs in 2004 (r 0·8810) and 2008 (r 0·8333). 
Considering their burden according to DALYs in 2004 and 
2008, trachoma, syphilis, and gonorrhoea are among the 
infections that are most underfunded, relative to all 
infections in the study. Hepatitis C, African 
trypanosomiasis, leishmaniasis, and malaria are among 
the infections that are most overfunded.
Funding for research with a clear paediatric focus 
was £87·1 million (3·3%), whereas investment for 
geriatric research was £7·2 million (0·3%). Health-care-
associated infections attracted £53·3 million (2·0%) of 
research funding.
When analysed by research and development pipeline 
(ﬁ gure 3), £1·6 billion (62·5%) of the investment was 
allocated to preclinical research, with smaller amounts 
(£146·8 million, 5·6%) allocated to clinical trial research 
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Figure 2: Association between investment and DALYs
Association between investment in speciﬁ c infection and DALYs in 2004 (Spearman’s correlation coeﬃ  cient [r] 0·5908 [A]). Investment in speciﬁ c infection and DALYs in 2008 (r 0·3688; p=0·0999 
[B]). Investment in disease system and DALYs in 2004 (r 0·8810 [C]). Investment in disease system and DALYs in 2008 (r 0·8333) using a logarithmic scale (D). DALYs=disability-adjusted life-years. 
HPV=human papillomavirus.
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and development stages (phases 1–3). Intervention and 
product development studies attracted 5·1% of invest-
ment (£132·9 million); these include phase 4 trials and 
the post-clinical trial assessment of medicines and 
devices in health care. Operational research studies 
attracted 26·8% of investment (£697·7 million). The 
relative contributions of each research and development 
value chain remained similar over the study period.
Seven institutions accounted for 88·4% of the total 
funding. The Wellcome Trust was the leading funder of 
infectious disease research, investing £688·3 million 
(26·4%) across 1985 studies, followed by the Medical 
Research Council investing a total of £672·9 million 
(25·8%) across 962 studies (appendix). Other prominent 
funding sources included the Biotechnology and Bio-
logical Sciences Research Council (BBSRC), the UK 
Department of Health, the European Commission, the 
Bill & Melinda Gates Foundation, and the combined 
investments of smaller charitable foundations.
The Bill & Melinda Gates Foundation awarded the 
largest mean grant per study (£5·7 million), followed by 
the European Commission (£1·2 million), the Medical 
Research Council (£699 000), the UK governmental 
departments (£611 104), the UK Department of Health 
(£473 500), the Wellcome Trust (£346 771), and the BBSRC 
(£322 262). A notable example of the type of grants awarded 
by the Bill & Melinda Gates Foundation is the £20 million 
donation in 2002 to establish the Schistosomiasis Control 
Initiative at Imperial College London.
Sources of funding by research phase vary greatly 
(table 2). The Medical Research Council was the leading 
funder of HIV and virology research, with £360 million 
of investments (36·0%). The Wellcome Trust is the 
leading funder of malaria and parasitology with £275 mil-
lion (41·7%), as well as bacteriology research, with 
£176 million (30·1%). The BBSRC is the leading funder 
of mycology research with £14·8 million (30·5%) and the 
UK Department of Health is the leading funder of 
research into prion disease with £20·2 million (60·2%).
Discussion
We identiﬁ ed 6170 funded studies, with a total research 
investment of £2·6 billion. Studies with a clear global 
health component represented 35·6% of all funding 
(£927 million), and the Wellcome Trust and Medical 
Research Council were the two leading funding sources. 
Preclinical research accounted for £1·6 billion (62·5%) of 
the total research and development invest ment. We 
highlight several major areas where there might be 
underinvestment—namely, for research focusing explicitly 
on infections in elderly people (£7·2 million, 0·3%) and in 
children (£87·1 million, 3·3%). Investment in some of the 
neglected tropical diseases, gastrointestinal infections, and 
sexually transmitted infections excluding HIV are also far 
lower than their global burden of disease would warrant.
Investment for drug-resistance-related research seems 
inadequate, since antimicrobial resistance across all 
areas of infection has been described by WHO as a global 
public health emergency aﬀ ecting all countries.14 Despite 
the expansion of the directly observed treat ment short-
course (DOTS) programme for tuberculosis, multidrug-
resistant tuberculosis is spreading unabated such that 
WHO now considers strains of extensively drug-resistant 
tuberculosis to be “virtually untreatable”.15 Future 
research investment in this area should increase in line 
with projected burden.
WHO data suggest that gastrointestinal infections and 
diarrhoeal disease account for high disease burden and 
mortality worldwide.1 However, the research spend for 
these disorders is substantially lower than other high 
burden and high proﬁ le diseases, such as HIV and malaria. 
In view of their relative burden, gastrointestinal infections, 
Figure 3: Distribution of cumulative funding by disease system and breakdown by research pipeline (A), and 
proportional breakdown of research pipeline within disease system (B)
0 100 000 000 200 000 000 300 000 000 400 000 000 500 000 000
Ocular
infections
Hepatic
infections
Drug-resistant
infections
Neurological
infections
Sexually transmitted
infections
Neglected tropical
diseases
Gastrointestinal
infections
Haematological
infections
Respiratory
infections
HIV
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Ocular
infections
Hepatic
infections
Drug-resistant
infections
Neurological
infections
Sexually transmitted
infections
Neglected tropical
diseases
Gastrointestinal
infections
Haematological
infections
Respiratory
infections
HIV
A
B
Preclinical
Phase 1–3
Product development
Operational research
Percentage funding by research phase
Cumulative funding in UK pounds
For the Schistosomiasis Control 
Initiative see http://www.
imperial.ac.uk/schisto
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and sexually transmitted infections should therefore be 
assigned a higher priority for improved research 
investment by funding organisations. There might be a 
reasonable argument for a proportionate increase in 
research related to health-care-associated infections, 
although there is also a lack of good quality data about 
burden in this area, particularly in low-income countries.
The burden of infectious diseases is particularly heavy 
on children, with 64% of worldwide deaths in children 
younger than 5 years related to infection.16 We show two 
key shortcomings for global infectious disease research 
in relation to children. First, investment in research for 
infections in children is generally very low, although 
malaria and vaccines, which mostly relate to children, 
attracted fairly high levels of funding. From 1997 to 2010, 
studies speciﬁ cally focusing on infectious diseases in 
children attracted £87·1 million across 307 studies, 
representing 3·3% of the total funding across 5·0% of 
the total studies. Second, studies relating to nutrition and 
paediatric infectious diseases were poorly funded despite 
the huge burden of morbidity and mortality worldwide in 
children due to malnutrition—a major cause of immune 
deﬁ ciency.17 Paediatric infectious disease studies with a 
nutrition component attracted £4·3 million across nine 
studies, representing only 5·0% of paediatrics funding 
and 0·2% of total funding.
Analysis by research and development value chain 
shows that the UK has invested heavily in preclinical 
research, but invested relatively small amounts in 
phase 1–4 trials or product development. This discrepancy 
might represent a strength of UK institutions in preclinical 
science, but it also highlights a need to strengthen 
research capacity further along the research and 
development value chain. There is also a need to obtain 
comparable data from other countries to under stand 
whether this spending pattern is representative. It would 
also be useful to gauge whether funders consider they 
receive a lack of high quality clinical grant appli cations 
compared with those in basic science. We noted a lack of 
readily available data from the pharmaceutical industry, 
greatly underestimating funding for clinical trials of 
pharmaceutical products; but this will probably make little 
diﬀ erence to estimates of funding for operational research.
Linking investments to disease burden to optimise the 
allocation of limited research funds is a challenging 
endeavour. Our ﬁ ndings could be used to develop 
transparent and objective methods to better couple 
research investment to burden of disease. Earlier 
analyses have broadly concluded that the ﬁ nancial spend 
is appropriate when DALYs are used as a measure of 
burden, but using measures of incidence or prevalence 
as a marker for burden of disease were insuﬃ  cient8–11 in 
view of the unreliability of incidence data and that im-
proved management of infections with a high mortality 
rate often lead to an increase in prevalence.18  However, 
deﬁ ning an appropriate amount of research investment 
for each disease category is challenging, since diﬀ erent 
levels of investment might be needed to address diseases 
with a similar level of public health burden. Emerging 
infections with unpredictable future disease burden such 
as prion disease, viral haemorrhagic fevers, or pandemic 
inﬂ uenza present particular challenges when establishing 
relative priority for investment.
Our ﬁ ndings are consistent with earlier studies that 
focused mainly on research and development spending 
for global infectious disease,7 showing the UK to be a 
leading funder of research and development, along with 
the USA and European Commission, and showing 
private sector contributions to neglected disease research 
to be an estimated US$503 million (£325·4 million) in 
2010. Although there is no breakdown by country, the 
data are categorised by disease area, with tuberculosis, 
malaria, and dengue attracting the most private 
investment. Investment by the pharmaceutical industry 
could aﬀ ect how other funders invest in research and 
development for infectious disease (no industry data is 
included in this analysis because of diﬃ  culties in openly 
accessing funding information),8 whereas research 
charities have their own speciﬁ c areas of focus that might 
constrain their ability to invest beyond selected diseases. 
A study of oﬃ  cial development assistance allocated for 
neglected tropical diseases shows low investment levels 
accounting for only 0.6% of annual health assistance 
between 2003 and 2007.19
Tracking the overall spend on all areas of global health 
ﬁ nancing is a complex task. This conclusion was based on 
several factors including fragmentation of data and 
paucity of detailed information from the private sector. 
A Global Health Resource Tracking Working Group 
reported in 2006 that calculating the amount of funding 
allocated to global health was too diﬃ  cult owing to several 
factors including tracking the large and diverse number of 
public and private sources of funding, and the nature of 
poorly designed donor accounting struc tures.20 A 
2009 study investigating global health funding 
recommended the provision of detailed descriptions of 
the funding provided to improve the eﬃ  ciency, account-
ability, performance, and equity of resource allocation of 
the many actors that populate the global health landscape.21 
One key recommendation of the Global Health Resource 
Tracking Working Group was to implement improved 
tracking and monitoring of global health ﬁ nancing. 
Within research, this improve ment can be achieved both 
worldwide and nationally, as earlier studies and our report 
show in the area of infectious diseases.
An important question inspiring our project is 
whether the right research is being funded. Although the 
competitive research process used by most funders when 
awarding grants can help ensure that the funded portfolio 
is of a high quality, absence of explicit resource allocation 
criteria means funding for research and development 
might not reach areas of highest burden. Funding 
agencies do have their own areas of focus, and thus UK 
funding agents might have factored other coun tries’ 
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investments into their own investment strategy. Data 
from other countries is essential to complete the 
mapping of investments. WHO budgets and global 
disease burden have been the centre of much debate.22–24 
The low proﬁ le of neglected tropical diseases despite a 
high disease burden against other tropical diseases such 
as malaria has been highlighted.25–27 Studies have also 
explored ways to maximise the eﬀ ect of operational 
research on policy and practice.28 Our ﬁ ndings build on 
these earlier studies and contribute to policy discussions 
relating to investment in research. They also inform 
funders of funding patterns among organisations 
ﬁ nancing re search and development, which can help 
prevent sub optimum investment of limited resources.
Showing the relation between health burden and 
research funding allows identiﬁ cation of areas of under-
investment. However, we cannot state with certainty that 
these gaps represent areas of neglect without factoring in 
several considerations. These factors include the 
feasibility of doing the research, the cost of the tech-
nologies involved, the presence or absence of suitable 
infrastructure and appropriately skilled individuals, local 
political and social conditions, and uncertainty around 
the accuracy of the estimates of disease burden.
Our analysis has several limitations. We rely on the 
accuracy of the original data from the funding organ-
isations; although checks were made on any apparent 
discrepancies or obvious errors, any interpretation of 
these original data is potentially ﬂ awed. No attempt was 
made to investigate any contribution of indirect and 
estate costs (including the introduction of full economic 
costing formulae in the UK), and currency conversions 
for donations in US dollars or Euros might not be 
precisely representative of the funding awarded because 
of ﬂ uctuations in ﬁ nancial markets across 1 year. Unless 
the information was clearly documented, we do not have 
data to assess how much funding was distributed from 
the lead institution to study partners.
Study numbers will be slightly inaccurate owing to 
diﬃ  culties ascertaining whether the funding was related 
to project extension or new study, and whether the 
funding was for a site as part of a multicentre study. 
Diﬀ erences in study reference numbers were used as a 
guide to distinguish between new studies and extensions 
and eﬀ ort made to identify multicentre trials.
Details of private sector research funding are diﬃ  cult 
to obtain and analyse in the level of detail we were able to 
apply to data obtained from public sector and charitable 
foundations. The National Research Register lists awards 
of research of direct relevance to the NHS from 1997 to 
2007. The register closed at the end of 2007. We could not 
openly access data for pharmaceutical industry in-house 
research and development investment, since much of 
this information is considered commercially sensitive. 
Individual awards of many millions of pounds for 
research into speciﬁ c diseases could skew the results. 
There are no data from the Chief Scientist Oﬃ  ce 
(Scotland) from 2008 to 2010, which might underestimate 
overall ﬁ gures for research and development.
We cannot ascertain what proportion of a grant 
should be allocated to each of the allocated disease 
categories. Hence, there might be disagreement about 
how the categories have been assigned. Some studies 
could not be allocated to categories since there was no 
clear implication of association with that category—for 
example hepatitis B could not be allocated to sexually 
transmitted infections unless this factor was suggested 
in the study title or abstract, owing to the pathogen’s 
many modes of transmission. Creation of disease 
categories and allocation of studies to the categories is 
subjective.
Burden measures are typically an estimate, since data 
could be missing, unobtainable, or subject to a diﬀ erent 
classiﬁ cation system or case diagnosis. Our analysis 
cannot easily account for the cross-disciplinary or 
geographical eﬀ ect of research.
Our report presents the latest ﬁ gures on investments in 
local and global infectious disease research awarded to 
UK institutions between 1997 and 2010 (panel). Neglected 
tropical diseases, gastrointestinal infections, sexually 
transmitted infections, and antimicrobial resistance seem 
to be areas warranting increased investment. We will 
make the entire database and ﬁ gures available online to 
assist policy makers, funding organisations, and fellow 
researchers in the identiﬁ cation of research gaps and 
infectious disease priorities (see margin link). We urge 
funding organ isations to make their investment portfolios 
Panel: Research in context
Systematic review
We searched PubMed for articles published at any time with 
the search terms “investments in research” and “infectious 
disease burden”, as well as “burden” and speciﬁ c infectious 
diseases or cross-cutting themes. We also searched for 
published reports with the same search terms. No publication 
investigating the investments in infectious disease research 
by the UK over time was identiﬁ ed.
Interpretation
Our study is the ﬁ rst to do a detailed assessment that the 
infectious disease research investments made by funding 
organisations to UK institutions. Health research investment 
decisions need to balance strategic insight into the burden of 
disease with judgments on scientiﬁ c quality and novelty. We 
identify inconsistencies of investment compared with the 
global burden of infection, suggesting the need for strategies 
to redress this imbalance. The scientiﬁ c and public health 
community, as well as governments and health departments, 
need to ensure limited resources are allocated appropriately 
and strategically. We encourage the support of similar 
open-access databases for non-communicable diseases and 
other countries, as well as further work comparing research 
funding with disease burden.
For the Research Investements 
in Global Health database see 
http://www.
researchinvestments.org
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openly accessible on this website by reporting their 
successful grants each year, as we have seen with the 
clinical trials registry ClinicalTrials.gov. We encourage the 
develop ment of similar databases for non-communicable 
dis eases and other countries, as well as further work on 
comparing research funding to disease burden.
High-quality research can allow substantial improve-
ments in redressing the infectious disease burden. As 
emphasised by the neglected tropical diseases move-
ment, increased funding and better-informed resource 
allocation could help control, eliminate, and eradicate 
infectious diseases.29 The scientiﬁ c and public health 
community, as well as governments and health depart-
ments, need to ensure limited resources are allocated 
appropriately and strategically, particularly with regards 
to health care and the alleviation of infectious disease 
morbidity and mortality.
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